All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
7 warning events since 2017; the latest 2026-03-11.
From the record
Yarrow Bioscience, Inc.'s filings since 2017 show 7 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-03-11); an auditor change (8-K item 4.01, 3 times, the latest 2022-04-07) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-23.1% a year over 8 filed years; profitable in 0 of 8.
From the record
Yarrow Bioscience, Inc.'s 8 filed years say what it did: revenue went from $4 million in fiscal 2018 to $570 thousand in fiscal 2025, down 23.1% a year; it rose in 3 of 7 years; the deepest fall was 98% from fiscal 2020 to fiscal 2023; net income was positive in 0 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Yarrow Bioscience, Inc.'s shareholder treatment is put at 0.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 1% of 51 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -95%: lost 95¢ per shareholder dollar. Leverage 8%: owes 8¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Yarrow Bioscience, Inc. lost about 95 cents for every dollar of shareholders' money. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 0.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 15% of 12 in its family; net margin -4646.1%.
From the record
Yarrow Bioscience, Inc.'s standing among 12 graded names in its industry family: revenue of $570 thousand in fiscal 2025 ranks in the bottom 13% by size; a net margin of -4646.1% ranks in the bottom 5%; revenue growth of 6.1% a year over the last 3 filed years ranks in the bottom 29% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 4.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Yarrow Bioscience, Inc.'s leadership is put at 4.7 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 47% of 63 in its family; the record of its people begins on 2026-07-29 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.8 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 36% of 9 in its family for room to expand.
From the record
Yarrow Bioscience, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $24 million against debt of $0 thousand leaves 79.7% of its assets as net cash, top 1% of its family; cash from operations less capital spending is -5811.2% of revenue (bottom 17%); research spending of 3374.9% of revenue (top 25%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 33% of 8 in its family for growth drivers.
From the record
Yarrow Bioscience, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 6.1% a year over the last three filed years against -23.1% over all 8, speeding up (top 6% of its family); the newest year grew 13.8% (top 44%); research spending grew 1.5% a year (top 50%) (its annual reports). Yarrow Bioscience, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 23% of 7 in its family for expectations against reality.
From the record
Yarrow Bioscience, Inc.'s newest year against its own record: revenue of $570 thousand in fiscal 2025 came in 11% above the $513 thousand its prior three years' pace pointed to (top 6% of its family); net income of $26 million against a prior three-year average of $30 million (bottom 44%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 7%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made